Related Experiment Video

Updated: Feb 28, 2026

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.4K

Percutaneous left ventricular assist devices in acute myocardial infarction complicated by cardiogenic shock

Holger Thiele1, Richard W Smalling, Gerhard C Schuler

  • 1Department of Internal Medicine/Cardiology, University of Leipzig--Heart Center, Strümpellstr. 39, 04289 Leipzig, Germany. thielh@medizin.uni-leipzig.de

European Heart Journal
|June 26, 2007
PubMed

Insights

Cardiogenic shock (CS) from acute myocardial infarction (AMI) has high mortality. Percutaneous left ventricular assist devices (LVADs) offer active circulatory support, potentially improving outcomes for patients unresponsive to standard treatments like intra-aortic balloon pumping (IABP).

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Critical Care Medicine

Background:

  • Cardiogenic shock (CS) is a critical complication of acute myocardial infarction (AMI), leading to significant mortality.
  • Intra-aortic balloon pumping (IABP) is a standard initial therapy but offers limited hemodynamic support, especially in severe left ventricular (LV) dysfunction.
  • Existing treatments may be insufficient for patients with profound LV dysfunction and persistent CS.

Purpose of the Study:

  • To review the current clinical experience with percutaneous left ventricular assist devices (LVADs) in patients with CS complicating AMI.
  • To evaluate the potential benefits of active circulatory support provided by LVADs in refractory CS.
  • To assess the role of LVADs as an alternative or adjunct to IABP in severe AMI-induced CS.

Main Methods:

  • Review of current literature and clinical data on the use of percutaneous LVADs in CS patients.
  • Analysis of hemodynamic outcomes and clinical efficacy of LVADs in the context of AMI-related CS.
  • Comparison of LVAD support with conventional therapies, including IABP, in managing severe CS.

Main Results:

  • Percutaneous LVADs provide active circulatory support, addressing limitations of IABP in severe LV dysfunction.
  • Early application of LVADs may improve hemodynamic stability and reverse CS in non-responders to standard therapy.
  • Data on the efficacy and safety of percutaneous LVADs in this specific patient population are emerging.

Conclusions:

  • Percutaneous LVADs represent a promising therapeutic option for cardiogenic shock complicating acute myocardial infarction, particularly in patients failing conventional management.
  • Active circulatory support from LVADs may offer superior hemodynamic benefits compared to devices like IABP.
  • Further research and larger studies are warranted to establish the definitive role of percutaneous LVADs in the treatment algorithm for AMI-induced CS.

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.2K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.7K

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.1K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
551
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
673
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
474
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
347